Unknown

Dataset Information

0

Structural basis for neutralization of hepatitis A virus informs a rational design of highly potent inhibitors.


ABSTRACT: Hepatitis A virus (HAV), an enigmatic and ancient pathogen, is a major causative agent of acute viral hepatitis worldwide. Although there are effective vaccines, antivirals against HAV infection are still required, especially during fulminant hepatitis outbreaks. A more in-depth understanding of the antigenic characteristics of HAV and the mechanisms of neutralization could aid in the development of rationally designed antiviral drugs targeting HAV. In this paper, 4 new antibodies-F4, F6, F7, and F9-are reported that potently neutralize HAV at 50% neutralizing concentration values (neut50) ranging from 0.1 nM to 0.85 nM. High-resolution cryo-electron microscopy (cryo-EM) structures of HAV bound to F4, F6, F7, and F9, together with results of our previous studies on R10 fragment of antigen binding (Fab)-HAV complex, shed light on the locations and nature of the epitopes recognized by the 5 neutralizing monoclonal antibodies (NAbs). All the epitopes locate within the same patch and are highly conserved. The key structure-activity correlates based on the antigenic sites have been established. Based on the structural data of the single conserved antigenic site and key structure-activity correlates, one promising drug candidate named golvatinib was identified by in silico docking studies. Cell-based antiviral assays confirmed that golvatinib is capable of blocking HAV infection effectively with a 50% inhibitory concentration (IC50) of approximately 1 ?M. These results suggest that the single conserved antigenic site from complete HAV capsid is a good antiviral target and that golvatinib could function as a lead compound for anti-HAV drug development.

SUBMITTER: Cao L 

PROVIDER: S-EPMC6493668 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Structural basis for neutralization of hepatitis A virus informs a rational design of highly potent inhibitors.

Cao Lei L   Liu Pi P   Yang Pan P   Gao Qiang Q   Li Hong H   Sun Yao Y   Zhu Ling L   Lin Jianping J   Su Dan D   Rao Zihe Z   Wang Xiangxi X  

PLoS biology 20190430 4


Hepatitis A virus (HAV), an enigmatic and ancient pathogen, is a major causative agent of acute viral hepatitis worldwide. Although there are effective vaccines, antivirals against HAV infection are still required, especially during fulminant hepatitis outbreaks. A more in-depth understanding of the antigenic characteristics of HAV and the mechanisms of neutralization could aid in the development of rationally designed antiviral drugs targeting HAV. In this paper, 4 new antibodies-F4, F6, F7, an  ...[more]

Similar Datasets

| S-EPMC5730766 | biostudies-literature
| S-EPMC7673538 | biostudies-literature
| S-EPMC3523860 | biostudies-other
| S-EPMC3150610 | biostudies-literature
| S-EPMC3202596 | biostudies-literature
| S-EPMC7199733 | biostudies-literature
| S-EPMC3386053 | biostudies-literature
| S-EPMC3121834 | biostudies-literature
| S-EPMC2981354 | biostudies-literature